Description: Reports of neurological problems in children taking the flu drugs Tamiflu and Relenza mean the medicines need a warning label on their packaging, according to a U.S. Food and Drug Administration safety review released Friday.

According to the Associated Press, the safety review follows 25 deaths among Tamiflu users under the age of 21, most of them occurring in Japan. In five cases, children fell from windows or balconies or ran into traffic, the AP said.

The FDA began its review in 2005 after receiving reports of children experiencing hallucinations, convulsions and other neurological problems while on Tamiflu.

Data from the review will be considered by a special panel of outside experts that will meet on Tuesday to mull the agency's proposed label changes. The FDA is not required to follow the advice of its advisory panels, but usually does.

According to the AP, there have so far been no child deaths linked to Relenza, but regulators say some children taking the drug have